Florian Janke
Overview
Explore the profile of Florian Janke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
129
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Janke F, Gasser M, Angeles A, Riediger A, Gortz M, Appenheimer L, et al.
J Exp Clin Cancer Res
. 2025 Mar;
44(1):87.
PMID: 40055810
Background: Outcomes under anti-PD-(L)1 therapy have been variable in advanced non-small cell lung cancer (NSCLC) without reliable predictive biomarkers so far. Targeted next-generation sequencing (NGS) of circulating tumor DNA (ctDNA)...
2.
Janke F, Stritzke F, Dvornikovich K, Franke H, Angeles A, Riediger A, et al.
Int J Cancer
. 2024 Aug;
156(4):853-864.
PMID: 39212345
Local recurrence after radiotherapy is common in locally advanced head and neck cancer (HNC) patients. Re-irradiation can improve local disease control, but disease progression remains frequent. Hence, predictive biomarkers are...
3.
Kunstner A, Schwarting J, Witte H, Xing P, Bernard V, Stolting S, et al.
Leukemia
. 2024 Apr;
38(5):1086-1098.
PMID: 38600314
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) constitutes a rare and aggressive malignancy originating from plasmacytoid dendritic cells (pDCs) with a primarily cutaneous tropism followed by dissemination to the bone marrow...
4.
Angeles A, Janke F, Daum A, Reck M, Schneider M, Thomas M, et al.
Br J Cancer
. 2023 Apr;
129(1):112-121.
PMID: 37120670
Background: Detection of circulating tumour DNA (ctDNA) in biological fluids is a minimally invasive alternative to tissue biopsy for therapy monitoring. Cytokines are released in the tumour microenvironment to influence...
5.
Eickelschulte S, Riediger A, Angeles A, Janke F, Duensing S, Sultmann H, et al.
Cancers (Basel)
. 2022 Dec;
14(24).
PMID: 36551580
Current strategies for the clinical management of prostate cancer are inadequate for a precise risk stratification between indolent and aggressive tumors. Recently developed tissue-based molecular biomarkers have refined the risk...
6.
Janke F, Angeles A, Riediger A, Bauer S, Reck M, Stenzinger A, et al.
Clin Epigenetics
. 2022 Dec;
14(1):163.
PMID: 36461127
Background: DNA methylation (5-mC) signals in cell-free DNA (cfDNA) of cancer patients represent promising biomarkers for minimally invasive tumor detection. The high abundance of cancer-associated 5-mC alterations permits parallel and...
7.
Schindler H, Lusky F, Daniello L, Elshiaty M, Gaissmaier L, Benesova K, et al.
Front Oncol
. 2022 Nov;
12:1010660.
PMID: 36387148
Introduction: PD-(L)1 inhibitors (IO) have improved the prognosis of non-small-cell lung cancer (NSCLC), but more reliable predictors of efficacy and immune-related adverse events (irAE) are urgently needed. Cytokines are important...
8.
Angeles A, Christopoulos P, Yuan Z, Bauer S, Janke F, Ogrodnik S, et al.
NPJ Precis Oncol
. 2021 Dec;
5(1):100.
PMID: 34876698
Targeted kinase inhibitors improve the prognosis of lung cancer patients with ALK alterations (ALK+). However, due to the emergence of acquired resistance and varied clinical trajectories, early detection of disease...
9.
Angeles A, Janke F, Bauer S, Christopoulos P, Riediger A, Sultmann H
Cancers (Basel)
. 2021 Nov;
13(22).
PMID: 34830770
Cell-free DNA (cfDNA) analysis using liquid biopsies is a non-invasive method to gain insights into the biology, therapy response, mechanisms of acquired resistance and therapy escape of various tumors. While...
10.
Christopoulos P, Dietz S, Angeles A, Rheinheimer S, Kazdal D, Volckmar A, et al.
Transl Lung Cancer Res
. 2021 Jun;
10(5):2118-2131.
PMID: 34164264
Background: Liquid rebiopsies can detect resistance mutations to guide therapy of anaplastic lymphoma kinase-rearranged (ALK) non-small-cell lung cancer (NSCLC) failing tyrosine kinase inhibitors (TKI). Here, we analyze how their results...